Changes/additions to materials:

29th March 2010: NICE has reissued its guideline on cardiovascular risk assessment and lipid modification (CG67) removing the recommendation to use a specific method for risk estimation (based on the Framingham equation).  NICE considered new evidence relating to QRISK but concluded that it was not able to recommend one cardiovascular risk estimation method over another. It has therefore left the decision to the NHS locally to use the method best suited to their requirements. All other recommendations in the guideline are unchanged. 

NICE guidance on CV risk assessment published
Since these materials were prepared, NICE has published guidance on CV risk assessment and lipid modification. The materials on this floor of NPCi are currently being updated and will be available shortly. In the meantime, key issues relating to the NICE recommendations are discussed in a blog and further information is available on the lipids floor of NPCi

Work through these two case studies to explore your understanding of cardiovascular risk assessment. The answers provided are examples of good practice, not neccessarily the only correct answer.

Case study 1 - A patient with low risk of CVD

Case study 2 - 44 year old man of South Asian origin with high risk of CVD

Date updated - January 2010